Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 02/08/2023

    Freiburg research team casts light on signal-dependent formation of mitochondria

    Known as the power plant of the cell, mitochondria are essential to human metabolism. Human mitochondria consist of 1,300 different proteins and two fatty biomembranes. The vast majority of mitochondrial proteins are produced with a cleavable transport signal and have to be actively transported into the mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freiburger-forschungsteam-klaert-signalabhaengige-bildung-von-mitochondrien-auf
  • Tumour organoids facilitate drug discovery - 20/07/2023 A woman in a white lab coat is sitting at a computer whose screen shows various miniature tumors after drug treatment.

    Drug screening for children with cancer using patient-specific miniature tumours

    Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.

    https://www.gesundheitsindustrie-bw.de/en/article/news/drug-screening-children-cancer-using-patient-specific-miniature-tumours
  • Press release - 23/06/2023

    The molecular control centre of our protein factories

    Researchers from Konstanz and Zurich have deciphered a biochemical mechanism that ensures that newly formed proteins are processed correctly when they leave the cell's own protein factories. This solves a decade-old puzzle in protein sorting.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-centre-our-protein-factories
  • Reduced immunosuppression possible in transplantations - 05/06/2023 Group photo of the founding team. Two younger men in light blue shirts and short hair and a woman with long dark hair in a white turtleneck jumper can be seen.

    Modified immune cells produce donor-specific tolerance

    Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modified-immune-cells-produce-donor-specific-tolerance
  • Press release - 20/01/2023

    Czech Inventor Award for Martina Benešová-Schäfer

    With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tschechischer-erfinderpreis-fuer-martina-benesova-schaefer
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Press release - 05/01/2023

    Formation of pores in mitochondrial membrane elucidated

    Mitochondria are considered to be the power plants of cells and are essential for human metabolism. Dysfunction in 40 percent of mitochondrial proteins are associated with human diseases, which is why mitochondria also play an important role in medical research. A previously unexplained process in the complex mitochondria was the formation of their barrel pores.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/formation-pores-mitochondrial-membrane-elucidated
  • Press release - 14/12/2022

    New drug for metastatic prostate cancer now also approved in Europe

    On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neues-medikament-gegen-metastasierten-prostatakrebs-nun-auch-europa-zugelassen
  • Neurodegenerative diseases - 12/12/2022 Darstellung mehrerer Neuronen mit langen Zellfortsätzen, zwischen denen sich kugelförmige Beta-Amyloid-Aggregate befinden. Die  Zellkörper sind von pTau-Fibrillen durchzogen.

    Blood-based biomarkers allow the early prediction of Alzheimer's risks

    Most dementia diseases develop insidiously and are only detected at an advanced stage. Researchers at the University of Heidelberg and the German Cancer Research Center (DKFZ) have now identified the glial fibre acidic protein (GFAP) in the blood as a promising biomarker that can be used to determine an increased risk of developing Alzheimer's disease up to 17 years before diagnosis.

    https://www.gesundheitsindustrie-bw.de/en/article/news/blood-based-biomarkers-allow-early-prediction-alzheimers-risks
  • Press release - 20/10/2022

    Cytoskeleton acts as cells’ bouncer for bacteria

    Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Press release - 21/09/2022

    ERC funding: How to deliver gene therapies to a specific target site?

    With its "Proof of Concept" grants, the European Research Council ERC supports scientists in further developing the commercial potential of their research results. Nina Papavasiliou from the DKFZ is now receiving the prestigious grant for the second time: she wants to advance the development of a "molecular delivery service" that ensures that therapeutic genes reach the right address in the body in a targeted manner.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-how-deliver-gene-therapies-specific-target-site
  • Press release - 19/09/2022

    How stressed tumor cells escape cell death: new mechanism discovered

    Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-stressed-tumor-cells-escape-cell-death-new-mechanism-discovered
  • Article - 14/09/2022 Radiodiagnostik von Prostatakrebs durch Positronen-Emissions-Tomografie

    Theranostics of prostate cancer: the combination of radionuclide diagnostics and radionuclide therapy

    Using a low-level radiopharmaceutical that binds to the prostate-specific membrane antigen (PSMA), positron emission tomography/computed tomography can be used to visualise even small prostate cancer metastases. Developed by Heidelberg researchers, the radiopharmaceutical is a modified radionuclide diagnostic agent that has been coupled with a powerful emitter and used as a therapeutic tracer to irradiate and destroy cancer cells from within.

    https://www.gesundheitsindustrie-bw.de/en/article/news/theranostics-prostate-cancer-combination-radionuclide-diagnostics-and-radionuclide-therapy
  • Press release - 31/08/2022

    Using nanopores to detect epigenetic changes faster

    Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-nanopores-detect-epigenetic-changes-faster
  • Hearing loss - 29/06/2022 vibrosonic-hoergeraet.jpg

    Innovative micro loudspeaker brings back hearing

    Hearing loss often severely restricts the lives of those affected and can only be partially reversed with conventional hearing aids. The innovative hearing aid developed by Vibrosonic GmbH from Mannheim transmits sound vibrations directly to the eardrum and can thus almost completely restore the natural hearing experience.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-micro-loudspeaker-brings-back-hearing
  • Press release - 29/06/2022

    RNA modifications in mitochondria promote invasive spread of cancer

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
  • Press release - 01/04/2022

    FDA approval for targeted radioligand therapy for treatment of metastatic prostate cancer

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center (DKFZ) and the University of Heidelberg. The agent significantly improves the chances of survival for those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approval-targeted-radioligand-therapy-treatment-metastatic-prostate-cancer
  • Biosensor for whole blood and exhaled breath analysis - 02/02/2022 Nahaufnahme eines Multiplex-Chips mit roten oder blauen Kanälen, der zwischen zwei Fingern in blauen Handschuhen gehalten wird.

    Antibiotic detection from whole blood or exhaled breath possible

    Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

    https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-detection-whole-blood-or-exhaled-breath-possible
  • Cluster of the future - 25/11/2021 NanodiagBW_Teaser.png

    nanodiagBW: using nanopores to create completely new diagnostic possibilities

    Modern medicine has a wide range of molecular diagnostics at hand. In the next decade, this will increasingly be supplemented by prognostic methods. The BMBF Cluster of the Future finalist, nanodiag BW, is developing prognostic methods to identify epigenetic factors for diseases through a new type of bioanalytics – single molecule analysis in nanopores – which would make it possible to take personalised prevention approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/news/nanodiagbw-using-nanopores-create-completely-new-diagnostic-possibilities
  • Press release - 25/05/2021

    From harmless skin bacteria to dreaded pathogens

    The bacterium Staphylococcus epidermidisis primarily a harmless microbe found on the skin and in the noses of humans. Yet some strains of this species can cause infections – in catheters, artificial joints, heart valves, and in the bloodstream – which are difficult to treat. These bacteria are often resistant to a particularly effective antibiotic, methicillin, and are among the most feared germs in hospitals.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/harmless-skin-bacteria-dreaded-pathogens
  • Press release - 17/02/2021

    A new piece of the HIV infection puzzle explored

    Researchers from EMBL and Heidelberg University Hospital combine high-resolution imaging to observe the infection process in cell nuclei, opening the door for new therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-piece-hiv-infection-puzzle-explored
  • Infection control - 07/01/2021 Elektronenmikroskopische Aufnahme von pink gefärbten Staphylococcus aureus Bakterien auf einer lila gefärbten Zelloberfläche.

    Gene accordions as potential markers for pathogenic properties

    Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-accordions-potential-markers-pathogenic-properties
  • Article - 26/07/2019 Jeney_Bild1.jpg

    New test assay leads to discovery of new influenza virus infection route

    Researchers from the University of Freiburg have recently discovered a completely new mechanism that influenza viruses use to infect cells. This discovery was partly made possible by a so-called emulsion coupling assay - an extremely sensitive, digital detection method developed by Actome GmbH in collaboration with scientists from the Freiburg University of Applied Sciences and Hahn-Schickard. The assay is used to count individual molecules and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/alternativer-infektionsweg-fuer-grippeviren-durch-neues-testverfahren-entdeckt
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses

Page 2 / 3

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search